Frouzandeh Mahjoubi

Dr. Frouzandeh Mahjoubi


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
PSPourya Sarvari
Pourya Sarvari
PSPouya Sarvari
Pouya Sarvari
IRIvonne Ramírez-Díaz
Ivonne Ramírez-Díaz
FMFrouzandeh Mahjoubi
Frouzandeh Mahjoubi
Karla RubioKarla Rubio
Karla Rubio
Epigenetic modifications are known to regulate cell phenotype during cancer progression, including breast cancer. Unlike genetic alterations, changes in the epigenome are reversible, thus potentially reversed by epi-drugs. Breast cancer, the most common cause of cancer death worldwide in women, encompasses multiple histopathological and molecular subtypes. Several lines of evidence demonstrated distortion of the epigenetic landscape in breast cancer. Interestingly, mammary cells isolated from breast cancer patients and cultured ex vivo maintained the tumorigenic phenotype and exhibited aberrant epigenetic modifications. Recent studies indicated that the therapeutic efficiency for breast cancer regimens has increased over time, resulting in reduced mortality. Future medical treatment for breast cancer patients, however, will likely depend upon a better understanding of epigenetic modifications. The present review aims to outline different epigenetic mechanisms including DNA methylation, histone modifications, and ncRNAs with their impact on breast cancer, as well as to discuss studies highlighting the central role of epigenetic mechanisms in breast cancer pathogenesis. We propose new research areas that may facilitate locus-specific epigenome editing as breast cancer therapeutics.

1 April 2011 in Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology
Verified
Journal Article
Closed access
AAArash Akbarzadeh
Arash Akbarzadeh
HFHamid Farahmand
Hamid Farahmand
FMFrouzandeh Mahjoubi
Frouzandeh Mahjoubi
MNMohammad Ali Nematollahi
Mohammad Ali Nematollahi
PLPiia Leskinen
Piia Leskinen
MNMikko Nikinmaa
Mikko Nikinmaa

1 July 2018 in The International Journal of Occupational and Environmental Medicine
Verified
Journal Article
Open access
PDF file
IJIraj Jamebozorgi
Iraj Jamebozorgi
TMTayebeh Majidizadeh
Tayebeh Majidizadeh
GPGholamreza Pouryaghoub
Gholamreza Pouryaghoub
FMFrouzandeh Mahjoubi
Frouzandeh Mahjoubi
Aberrant DNA Methylation of Two Tumor Suppressor Genes, p14 ARF and p15 INK4b , after Chronic Occupational Exposure to Low Level of Benzene

1 May 2005 in Cytogenetic and Genome Research
Verified
Journal Article
Closed access
PDF file
FMFrouzandeh Mahjoubi
Frouzandeh Mahjoubi
GPG.B. Peters
G.B. Peters
PMP. Malafiej
P. Malafiej
CSC. Shalhoub
C. Shalhoub
ATA. Turner
A. Turner
RHR.J. Hill
R.J. Hill
A small, mosaic, C-band negative marker chromosome was detected in amniocyte cultures during prenatal diagnosis due to advanced maternal age. Following spontaneous premature labor at 29 weeks gestation, a dysmorphic infant was delivered, with flat nasal bridge, short palpebral fissures, micrognathia, high forehead, low-set ears, telecanthus and corneal dystrophy. Additional folds of skin were present behind the neck, and feet, fingers and toes were abnormally long. The child died at age five days, after two days of renal failure. The origin of the marker chromosome was subsequently identified from a cord blood sample, via chromosome microdissection. Through reverse FISH, we found the marker to be an inverted duplication of the region 15q26.1→qter. FISH with alphoid satellite probe was negative, while whole chromosome 15 paint was positive. Both ends of the marker chromosome were positive for the telomeric TTAGGG probe. These data, plus the G-banding pattern, identified the marker as an analphoid, inverted duplicated chromosome, lacking any conventional centromere. We discuss the etiology and clinical effects of this marker chromosome, comparing it to the few reported cases of “tetrasomy 15q” syndrome. We also discuss the possible mechanisms that are likely responsible for this neocentromere formation.

1 May 2008 in Sao Paulo Medical Journal
Verified
Journal Article
Open access
PDF file
FMFrouzandeh Mahjoubi
Frouzandeh Mahjoubi
MGMasoud Golalipour
Masoud Golalipour
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
KAKamran Alimoghaddam
Kamran Alimoghaddam
CONTEXT AND OBJECTIVE: Overexpression of the multidrug resistance-associated protein 1 (MRP1) gene has been linked with resistance to chemotherapy in vitro, but little is known about its clinical impact on acute leukemia patients. Our aim was to investigate the possible association between MRP1 gene expression level and clinical outcomes among Iranian leukemia patients. DESIGN AND SETTING: This was an analytical cross-sectional study on patients referred to the Hematology, Oncology and Stem Cell Research Center, Sharyatee Public Hospital, whose diagnosis was acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL). All molecular work was performed at NIGEB (public institution). METHODS: To correlate with prognostic markers and the clinical outcome of acute leukemia, MRP1 gene expression was assessed in 35 AML cases and 17 ALL cases, using the quantitative real-time polymerase chain reaction and comparing this to the chemotherapy response type. RESULTS: Mean expression in AML patients in complete remission (0.032 ± 0.031) was significantly lower than in relapsed cases (0.422 ± 0.297). In contrast, no significant difference in MRP1 mRNA level was observed between complete remission and relapsed ALL patients. There was a difference in MRP1 expression between patients with unfavorable and favorable cytogenetic prognosis (0.670 ± 0.074 and 0.028 ± 0.013, respectively). MRP1 expression in M5 was significantly higher (p-value = 0.001) than in other subtypes. CONCLUSIONS: The findings suggest that high MRP1 expression was associated with poor clinical outcome and was correlated with the M5 subtype and poor cytogenetic subgroups among AML patients but not among ALL patients.

3 December 2009 in Hemoglobin
Verified
Journal Article
Closed access
MHMohammad Hamid
Mohammad Hamid
FMFrouzandeh Mahjoubi
Frouzandeh Mahjoubi
MAMohammad T. Akbari
Mohammad T. Akbari
AAAida Arab
Aida Arab
SZSirous Zeinali
Sirous Zeinali
MKMorteza Karimipoor
Morteza Karimipoor
The nucleotide (nt) variations in the promoter region of the gamma-globin genes, HS-111 and 3'HS1 regions, were studied in Iranian patients with beta-thalassemia intermedia (beta-TI), beta-thalassemia major (beta-TM) and healthy individuals. Of the five nt variations at the 5' end of the (A)gamma-globin gene, -369 (C>G), -611 (-T) and -603/604 (GA>AG) were found in all samples, whereas -588 (A>G) and -AAGC at -222 to -225 were found at different frequencies in the studied groups. Therefore, the -369, -611 and -603/604 variations were considered common mutations in this population, and the difference with respect to the -AAGC deletion was not significant. However, the A allele of the -588 variation and [+] allele of the XmnI polymorphism were more frequent in beta-TI patients, especially those who had the IVS-II-1(G>A)/IVS-II-1(G>A) genotype. The + allele of XmnI also had complete correlation with the A allele of -588 variation. The HS-111 (-21 A) variation also showed association with beta-TI patients who had high levels of Hb F. Bearing in mind that the -588 variation lies within the postulated adult-specific silencer region and that the majority of beta-TI patients had allele A, then it can be envisaged that this allele could have a role in altering the repressor function at this region. Therefore, the A allele of -588, [+] allele of XmnI and HS-111 (-21 A) variation are useful genetic markers to differentiate between beta-TM and beta-TI patients. However, these nt changes alone may not be the only elements raising the level of Hb F, other regulatory and modifying factors also play a role in Hb F production.